Patient profiles

THE CDC'S ACIP RECOMMENDS PREVNAR 13® FOR IMMUNOCOMPROMISED ADULTS AGED ≥19 AND FOR IMMUNOCOMPETENT ADULTS AGED ≥65 BASED ON SHARED CLINICAL DECISION-MAKING1

Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a vaccine approved for adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine. Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication.

Learn more about adult patients who may be appropriate candidates for vaccination with Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

These patient profiles are hypothetical in nature and are not meant to represent specific individuals.

Aged 65 and older in good health

Nancy, 65 years of age

​​​​Medical history

  • Does yoga 5 days per week
  • ​​​​​​​Has mildly elevated cholesterol, currently managed with diet and exercise
  • ​​​​​​​Pneumococcal vaccine naïve

Risk factor for pneumococcal pneumonia

  1. 65 years of age​​​​​​​

Healthy adults aged 65 and older can face a 3.8x greater risk for pneumococcal pneumonia vs healthy 18- to 64-year-olds3

Announcement Title

Because Nancy is 65 years of age and is pneumococcal vaccine naïve, Prevnar 13® is recommended by the CDC based on shared clinical decision-making. When the decision to administer Prevnar 13® is made, it should be given first in series with Pneumovax 23®. Pneumovax 23® is routinely recommended in this patient.1

Aged 65 and older with diabetes

Iris, 67 years of age

Medical history

  • Diagnosed with type 2 diabetes at 55 years of age
  • Vaccinated with PPSV23 at diagnosis

Risk factors for pneumococcal pneumonia

  1. 67 years of age
  2. Diabetes

Adults aged 65 and older with diabetes can face a 2.8x greater risk for pneumococcal pneumonia vs healthy adults aged 65 and older3

Announcement Title

Because Iris is 67 years of age and also has diabetes, she is at increased risk for pneumococcal pneumonia. Prevnar 13® is recommended by the CDC based on shared clinical decision-making. When the decision to administer Prevnar 13® is made, it should be given first in series with Pneumovax 23® at least one year apart.1 Pneumovax 23® is routinely recommended in adults 65 and older.​​​​​​​

Aged 65 and older with chronic heart disease (CHD)

Ernie, 65 years of age

Medical history

  • Current smoker diagnosed with CHD at the age of 63
  • Recently retired, but remains active
  • ​​​​​​​Pneumococcal vaccine naïve

Risk factors for pneumococcal pneumonia

  1. 65 years of age
  2. Current smoker
  3. CHD

Adults aged 65 and older with two underlying medical conditions can face a 4.2x greater risk for pneumococcal pneumonia vs healthy adults aged 65 and older1

Announcement Title

Because Ernie is 65 years of age, a current smoker, and also has a CHD diagnosis, he is at increased risk for pneumococcal pneumonia. Prevnar 13® is recommended by the CDC based on shared clinical decision-making. When the decision to administer Prevnar 13® is made, it should be given first in series with Pneumovax 23®. Pneumovax 23® is routinely recommended in this patient.1

Chronic obstructive pulmonary disease (COPD) on high-dose oral corticosteroids (OCS)

Timothy, 59 years of age

Medical history

  • Diagnosed with COPD at the age of 50 years
  • Vaccinated with PPSV23 at the time of diagnosis
  • Prevnar 13® naïve 
  • ​​​​​​​Currently treated with high-dose OCS

Risk factors for pneumococcal pneumonia

  1. Diagnosis of COPD 
  2. Currently treated with high-dose OCS 
  3. Chronic/current smoker

Adult patients under 65 taking immunosuppressive medications such as high-dose OCS can face a 7.5x greater risk for pneumococcal pneumonia vs age-matched controls3

Announcement Title

Due to Timothy’s immunosuppressive treatment for his COPD, the CDC’s ACIP recommends that he receive 2 different pneumococcal vaccinations in series, starting with Prevnar 13®1 

Timothy has already received PPSV23 and is now due to receive Prevnar 13®​​​​​​​

Rheumatoid arthritis (RA) on disease-modifying antirheumatic drugs (DMARDs)

Debbie, 52 years of age

Medical history

  • Diagnosed with RA
  • Initiating treatment with DMARDs
  • ​​​​​​​Pneumococcal vaccine naïve

Risk factor for pneumococcal pneumonia

  1. Initiating treatment with DMARDs

Adult patients under 65 taking immunosuppressive medications such as DMARDs can face a 7.5x greater risk for ​​pneumococcal ​​​​​​​pneumonia vs age-matched controls3

Announcement Title

Due to Debbie’s immunosuppressive treatment for her RA, the CDC’s ACIP recommends that she receive 2 different pneumococcal vaccinations in series, starting with Prevnar 13®1

Chronic renal failure (CRF)

Jeffrey, 48 years of age

Medical history

  • Diagnosed with CRF
  • Treated with dialysis for the past 18 months
  • Diagnosed with diabetes at the age of 38 years
  • ​​​​​​​Pneumococcal vaccine naïve

Risk factors for pneumococcal pneumonia

  1. Diagnosis of CRF
  2. Diagnosis of diabetes

Adult patients under 65 with CRF can face a ​14.4x greater risk for pneumococcal pneumonia vs age-matched controls3

Announcement Title

Due to Jeffrey’s CRF, the CDC’s ACIP recommends that he receive 2 different pneumococcal vaccinations in series, starting with Prevnar 13®1 ​​​​​​​

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; CHD=chronic heart disease; PPSV23=23-valent pneumococcal polysaccharide vaccine.

Coverage & Reimbursement

Prevnar 13® is covered by the Medicare Part B fee-for-service (FFS) benefit for adults aged 65 and older with $0 in out-of-pocket costs2

Learn more

About

  • CDC's ACIP adult recommendations
  • Patient profiles

Order Prevnar 13®

Order vaccines directly through Pfizer's online ordering system

Order now

References:
  1. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:1069-1075. doi: http://dx.doi.org/10.15585/mmwr.mm6846a5.
       
  2. Department of Health & Human Services (DHHS). CMS Manual System. Pub 100-02 Medicare Benefit Policy. Transmittal 202. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R202BP.pdf. Accessed January 7, 2020.
       
  3. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1-9. doi:10.1093/ofid/ofu024.

Indication

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.

Please see full Prescribing Information for Prevnar 13®.

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine